BIOPRENEURS BITES from California Takshila University
BIOPRENEURS BITES from California Takshila University
********************************************************************************
-----------------------------------------------------------------------------------
Global Health Progress Joins WHO and DNDi to Call For Increased Commitments to Fighting Neglected Tropical Diseases
The worldwide pharmaceutical industry is joining the World Health Organization (WHO) and the Drugs for Neglected Diseases initiative (DNDi) in calling on the G-8 nations the importance of neglected diseases as a global health threat and a major strain on the economic viability and educational development of communities worldwide.
The newly formed Alliance urged G-8 to finance successful treatment and prevention programs, to support innovative strategies that address the challenging health gaps in developing countries, and to fund research and development to develop improved diagnostic, treatment and prevention options.
Most international attention is focused on HIV/AIDS, tuberculosis, malaria and global health security. However, neglected tropical diseases - most of which are preventable and treatable - remain major causes of death and disability worldwide. These diseases receive less funding and less attention while they decrease productivity, negatively affect quality of life and increase poverty throughout the developing world.
*********************************************************************************
India's Hepatitis B Virus Drug Market Will Grow Ten-Fold by 2012
*********************************************************************************
Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, forecasts that the Indian hepatitis B virus drug market will grow ten-fold by 2012, from $1.7 million in 2007 to $17 million in 2012. According to the new Emerging Markets report entitled Hepatitis B Virus in India, this growth will be fueled by a growing awareness of the hepatitis B virus and the growth of individual wealth among India's urban middle and upper class.
Additionally, the report finds that the number of prevalent cases of chronic hepatitis B virus in India (30.6 million in 2007) is three times that of the United States, France, Germany, Italy, Spain, United Kingdom and Japan combined. However, both diagnosis rates and drug treatment rates in India are extremely low.
**********************************************************************************
China's Hepatitis B Virus Drug Market Will Grow to $800 Million by 2012
*****************************************************************************************
Decision Resources also finds that the Chinese hepatitis B virus drug market will more than double by 2012, from $340 million in 2007 to $800 million in 2012. Both nucleoside/nucleotide analogues (NAs) and immunomodulators will experience strong double-digit growth, contributing to a robust 18 percent annual growth of the total market.
According to the new Emerging Markets report entitled Hepatitis B Virus in China, the greatest contributor to the growth of the Chinese hepatitis B drug market is the sheer size and nature of the epidemic in China- approximately 80 million Chinese people have chronic hepatitis B. Because treatment with nucleoside/nucleotide analogues is typically long-term (in many cases, lifelong), even steady diagnosis and drug-treatment rates would generate sizable near-term growth in this market. Government-sponsored improvements to the healthcare system and increasing economic prosperity among the Chinese population have also added to this market growth.
BIOPRENEURS BITES from California Takshila University - To learn more about this author, visit Ryan Baidya's Website.
Like this article? Share it with your friends
One billion people suffer from preventable, treatable diseases around the world
********************************************************************************
-----------------------------------------------------------------------------------
Global Health Progress Joins WHO and DNDi to Call For Increased Commitments to Fighting Neglected Tropical Diseases
The worldwide pharmaceutical industry is joining the World Health Organization (WHO) and the Drugs for Neglected Diseases initiative (DNDi) in calling on the G-8 nations the importance of neglected diseases as a global health threat and a major strain on the economic viability and educational development of communities worldwide.
The newly formed Alliance urged G-8 to finance successful treatment and prevention programs, to support innovative strategies that address the challenging health gaps in developing countries, and to fund research and development to develop improved diagnostic, treatment and prevention options.
Most international attention is focused on HIV/AIDS, tuberculosis, malaria and global health security. However, neglected tropical diseases - most of which are preventable and treatable - remain major causes of death and disability worldwide. These diseases receive less funding and less attention while they decrease productivity, negatively affect quality of life and increase poverty throughout the developing world.
*********************************************************************************
India's Hepatitis B Virus Drug Market Will Grow Ten-Fold by 2012
*********************************************************************************
Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, forecasts that the Indian hepatitis B virus drug market will grow ten-fold by 2012, from $1.7 million in 2007 to $17 million in 2012. According to the new Emerging Markets report entitled Hepatitis B Virus in India, this growth will be fueled by a growing awareness of the hepatitis B virus and the growth of individual wealth among India's urban middle and upper class.
Additionally, the report finds that the number of prevalent cases of chronic hepatitis B virus in India (30.6 million in 2007) is three times that of the United States, France, Germany, Italy, Spain, United Kingdom and Japan combined. However, both diagnosis rates and drug treatment rates in India are extremely low.
**********************************************************************************
China's Hepatitis B Virus Drug Market Will Grow to $800 Million by 2012
*****************************************************************************************
Decision Resources also finds that the Chinese hepatitis B virus drug market will more than double by 2012, from $340 million in 2007 to $800 million in 2012. Both nucleoside/nucleotide analogues (NAs) and immunomodulators will experience strong double-digit growth, contributing to a robust 18 percent annual growth of the total market.
According to the new Emerging Markets report entitled Hepatitis B Virus in China, the greatest contributor to the growth of the Chinese hepatitis B drug market is the sheer size and nature of the epidemic in China- approximately 80 million Chinese people have chronic hepatitis B. Because treatment with nucleoside/nucleotide analogues is typically long-term (in many cases, lifelong), even steady diagnosis and drug-treatment rates would generate sizable near-term growth in this market. Government-sponsored improvements to the healthcare system and increasing economic prosperity among the Chinese population have also added to this market growth.
BIOPRENEURS BITES from California Takshila University - To learn more about this author, visit Ryan Baidya's Website.
Like this article? Share it with your friends
| |||
 |
No article feedback found. | ||
|
Leave Your Feedback | ||
|
|||
 Talking In Media Morse Code
| |||
| Keep in mind, you want a couple of sound bites that you can pepper into the conversation, but you definitely do not want your entire conversation to be a series of sound bites. |
|||
|
What is Obama -The Politepreneur(c) - California Takshila University
| |||
| OBAMA, the politepreneur, is neither 100% African, nor 100% European nor 100% Mongolian (Asian). He is 100% AMERICAN -a race that comprise of all the genetics-material of the world - An entrepreneur in Politics.
... |
|||
|
The Men Behind MySpace: How Chris DeWolfe and Tom Anderson First Met
| |||
 “It sounds crazy,” says Chris DeWolfe, “but even in the first plan that I wrote up, I mentioned AOL, Yahoo! and Hotmail, knowing we would be big. And it’s crazy to think that it happened.” |
|||
|
Snappy Sound Bites Will Turn a TV Appearance Into A Huge Success
| |||
| Prepare some clever answers and snappy sound bites ahead of time, rehearse them every day and you’ll sound like a pro turning your TV appearance into a huge success. |
|||
|
One Copy at a Time: Kinko’s Takes Off
| |||
 Orfalea had been a student at USC when he noticed a copy machine in the school library. He realized that few people had access to the new technology and decided to do something about it. With a $5,000 loan from the ... |
|||
| |||
David BarrDavid Barr is the President of Venture Opportunities, Inc. David has been a professional business broker/intermediary since 1980 focusing on General Business Brokerage and Mergers and Acquisitions representing client transaction value from $400,000 to $20,000,000. Mr. Barr has handled the sale of over four hundred and fifty companies. David earned a university degree from the State University of New York majoring in economics and business. David holds the Mergers and Acquisition Master Intermediary and the Certified Business Intermediary designations from the International Business Brokers Association. He is also a Senior Business Analyst and a Texas licensed Real Estate Agent. For more information about David and Venture Opportunities, visit www.bizdealmaker.com. - Visit David Barr's Website |
|||
Linda RichardsonLinda Richardson is the Founder and Executive Chairwoman of Richardson, a global sales training and performance improvement company. As a recognized leader in the industry, she has won the coveted Stevie Award for Lifetime Achievement in Sales Excellence and she was identified by Training Industry, Inc. as one of the “Top 20 Most Influential Training Professionals.” Ms. Richardson is credited with the movement to Consultative Selling and is the author of ten books on selling and sales management, including Sales Coaching — Making the Great Leap from Sales Manager to Sales Coach, and Stop Telling, Start Selling. She teaches sales and management at the Wharton Graduate School of the University of Pennsylvania and the Wharton Executive Development Center. Linda is a frequent speaker at industry and client conferences, has been published extensively in industry and training journals, and has been featured in numerous publications, including The Wall Street Journal, Forbes, Nation’s Business, Selling Power, Success, and The Conference Board Magazine. Learn more about Richardson's sales training and performance improvement solutions at http://www.richardson.com web - Visit Linda Richardson's Website |
|||
|
To learn more about the Evan Elite Author Program please contact us. | |||
 | |
 Ryan Baidya (Visit Ryan's Website) Dr. Ryan Baidya is an entrepreneur a business strategist and who has 12+ years of experience in biotech. He launched several biotech and high-tech businesses in Silicon Valley/USA, and Tokyo/Japan. He founded BioZak and BioZak-Infobase, and served as one of the founding management. Prior to that he was with Genprobe, , HyseQ; and GeneAsia. He serves as an advisor to Golden-Embryo, Pune/India; and KZAISoft corp., Durgapur/India. He gave numerous lectures on life sciences and bio-business topics at conferences, primarily in USA, and Japan. He authored articles, patents, and commentaries. Dr. Baidya received his MS from IIT Kanpur, PhD from the University of California, Santa Cruz and MBA from the San Jose State University, CA. Currently he teaches at California Takshila University.
|  |
 |
|
|
 |
|
|
|
 |
| Modeling the Masters: Learn the true secrets behind Walt Disney's business success factors & grow your company! Video produced by Phanta Media |
|
|
 |
| Have you written articles that would be of value to entrepreneurs? Become an expert on our site by publishing them! Expose yourself to a wide audience, drive more traffic to your website and get more sales! Click Here for details. |
 |
 | ||
 |
||
 |
||
 |
||
|
| ||
|
|
|
Get advice & tips from famous business owners, new articles by entrepreneur experts, my latest website updates, & special sneak peaks at what's to come!
|
|
|
 |
 Crazy Busy Start Right Strategic Planning Guide Network More Effectively 25 Facebook & Twitter Tips |
|
 | ||
 |
Top 50 Blogs For Startups
Top Blogs To Watch In 2008 | |
|
Top 50 Blogs For Startups
Top Blogs To Watch In 2009 | |
| ||
 |
|
|
|
|
||||||||||||||||||||||||
 |
|
|
||||||||||||
